New Study Demonstrates Zephyr Endobronchial Valves Significantly Improve Breathing, Mobility and Quality of Life for Emphysema Patients
Pulmonx® Corp. today announced the publication of positive six-month results from TRANSFORM, a multicenter, multinational, randomized clinical trial (RCT) of the Zephyr® Endobronchial Valve (EBV®) in The American Journal of Respiratory and Critical Care Medicine.
According to the authors, Zephyr EBV treatment “results in clinically meaningful and statistically significant benefits in lung function, dyspnea, exercise tolerance and quality of life over current standard of care medical therapy” when used in heterogeneous emphysema patients with hyperinflation and no collateral ventilation in the target lung lobe.
The authors conclude that, “Benefits are in line with those seen with LVRS (lung volume reduction surgery), and the consistent trial results, potential reduction in post-procedure morbidity, and reversibility of the procedure position Zephyr EBV as a viable treatment option in those who remain symptomatic on maximal medical therapy.”
The TRANSFORM trial was conducted at 17 centers in six European countries and enrolled 97 patients with heterogeneous emphysema and no collateral ventilation in the target lobe, as determined by the company’s Chartis® System. Patients were randomized 2:1 to Zephyr EBV treatment versus optimal medical therapy.
The study met its primary endpoint, with 67 percent of patients having a 12 percent or greater improvement in lung function (FEV1) at three months in the per protocol group, compared to seven percent in the control group. In the intention-to-treat population at six months, Zephyr EBV patients experienced clinically and statistically greater improvements over the control group across multiple outcome measures, including lung function (29.3 percent increase in FEV1), exercise capacity (78.7m increase in 6MWD), and quality of life (6.5 point decrease in SGRQ score). A majority of EBV patients had an improvement of one or more points in the BODE index, an aggregate measure of health status, which has been associated with a significant decrease in mortality in this population.
Patients in the control arm were allowed to cross over to Zephyr EBV treatment at six months, if desired; 94 percent of control patients opted for Zephyr treatment following their assessments at six months.
The most common serious adverse event seen in the trial was a pneumothorax, which occurred in 29 percent of patients. For comparison, 90 percent of lung volume reduction surgery patients, and four to 42 percent of patients undergoing CT-guided biopsy, experience such events. The study authors noted that the occurrence of pneumothorax does not appear to negatively impact clinical outcomes.
“Zephyr EBV treatment delivers benefits similar to those seen with surgery, with the added benefit of being suitable for a broader range of patients,” said lead author, Dr. Samuel Kemp of the Royal Brompton Hospital in London, England.
Zephyr Endobronchial Valves are tiny, minimally-invasive, one-way valves placed via a flexible bronchoscope in airways of the lungs to occlude diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions can function more efficiently, enabling better breathing and an improved quality of life for patients.
“This was one of the most rigorous studies of the Zephyr EBV done to date in emphysema patients with heterogeneous emphysema and one or more lobes without collateral ventilation,” said Pulmonx Chief Executive Officer Glen French. “TRANSFORM shows definitive evidence of the tremendous benefit our technology can bring to patients who otherwise suffer from difficult breathing and are at high risk of morbidity and mortality. It is gratifying to be able to bring new hope to this underserved patient group.”
Over the past 10 years, approximately 50,000 Zephyr EBVs have been implanted globally in more than 12,000 patients. To view a video of the Zephyr EBV procedure, click here.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.
The Zephyr Endobronchial Valve is an investigational device in the United States. Limited by U.S. law to investigational use only.
+1 (949) 545 6654 or +1 (310) 902 1274
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
German Court Rules Huawei, ZTE Products Infringe AVC Patents16.11.2018 05:01 | Pressemelding
MPEG LA announced today that the District Court in Düsseldorf, Germany (“Landgericht Düsseldorf”) has ruled that Huawei Technologies Deutschland GmbH (“Huawei”) and ZTE Deutschland GmbH (“ZTE”) infringed patents of two patent holders in MPEG LA’s AVC Patent Portfolio License (“AVC License”) by using their technologies in mobile phones that implement the AVC/H.264 (MPEG-4 Part 10) Standard. The court also found that the license offered by the patent holders under those patents through the AVC License is fair, reasonable and nondiscriminatory. “The Landgericht Düsseldorf’s decision confirms the importance of respect for intellectual property, and offering everyone easy and affordable access to essential AVC technology under a single license is a cornerstone of the MPEG LA AVC License’s wide acceptance making that possible,” said Larry Horn, President and CEO of MPEG LA. “We continue to welcome Huawei and ZTE to join the nearly 2,000 Licensees who have entered into our AVC License.” Verdi
IFF-LMR Naturals Leads Industry with 90 Certified Vegan Natural Extracts15.11.2018 21:15 | Pressemelding
Regulatory News: IFF-LMR, a subsidiary of International Flavors & Fragrances Inc (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) announced their industry-leading position of 90 natural extracts in their portfolio certified vegan by the EVE (Expertise Vegan Europe) VEGAN standards. The certified extracts include Rose EssentialTM, Rose UltimateTM, Blackcurrant Buds Absolute, Ylang Oil Complete, Vetiver Oil Haiti, Patchouli Oil Indonesia, and Geranium Heart Oil, among many others. Bertrand de Preville, General Manager, IFF-LMR said, “Our people are passionate about creating the finest ingredients and together, we are committed to delivering premium, 100% pure and natural extracts. We believe in transparency, environmental management and sustainable development.” Mr. de Preville continued, “This certification of 90 extracts is in line with IFF-LMR’s continuous dedication to our planet, people, plants and animals.” The EVE VEGAN label was selected because it is considered one of the most rigor
Rimini Street Expands Investment and Operations in Asia-Pacific15.11.2018 20:00 | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that it has expanded its operations in the Asia-Pacific region with the launch of its new subsidiary, Rimini Street New Zealand Limited, and the opening of its new office in Auckland to address the growing demand for Rimini Street’s premium, ultra-responsive support services in New Zealand. Rimini Street’s expansion was announced at a gala event held at The Northern Club in Auckland, where clients, local IT leaders and the special guest of honor, Ambassador Scott P. Brown, the U.S. Ambassador to New Zealand, were hosted by Rimini Street’s general manager for Asia-Pacific, Andrew Powell, and Rimini Street corporate senior executives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005037/en/ Rimini Street launches subsidiary
Sartorius Stedim Biotech and Lonza Modify Relationship for Supply of Cell Culture Media15.11.2018 18:15 | Pressemelding
Sartorius Stedim Biotech (SSB) (Paris:DIM), a leading international supplier of the biopharmaceutical industry, and Lonza announced today that they have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave SSB exclusive sales and marketing rights for certain cell culture media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among others. Under agreements signed today, SSB will continue to offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing. Lonza Pharma & Biotech resumes sales and marketing of all its media products for both manufacturing and research. Customers of both companies will continue to be able to source media products for their specific needs. “We have a long-standing and productive partnership
Intertops Poker Launches its 20 Event Strong SOFT Series for its Recreational Player Base15.11.2018 17:46 | Pressemelding
Intertops Poker has launched a new tournament series aimed and created for its recreational and casual player base, with impressive prizes up for grabs. The Intertops Poker SOFT Series is spread across 20 events and offers a combined prize pool of $24,850, including a $4,100 World Series of Poker Caribbean prize package. The series starts on 19th November and will conclude on 25th November. It is available to players from all countries and markets wanting to test their skills and have fun at the tables. There are a wide range of buy-ins to suit all budgets, and the tournament kicks-off with two $500 freerolls before the series gets underway proper on 20th November. Each SOFT Series event winner will receive an Intertops Poker Soft Series Champion hoodie and a seat at the table for the Champions Tournament. The highlight of the series, the Champions Tournament takes place on 25th November at 6:30pm ET and has a guaranteed World Series of Poker Caribbean prize worth $4,100. The World Ser
Telstra: Capital Planning & Delivery Named PMO of the Year15.11.2018 17:21 | Pressemelding
Today, Project Management Institute (PMI), the world’s leading association for the project, program and portfolio management profession, announced that Telstra: Capital Planning & Delivery (Melbourne, Australia) has been awarded the 2018 PMO of the Year Award. In 2012, Telstra created the Capital Planning and Delivery (CP&D) function as a dedicated capability within the Finance and Strategy organization. Their purpose was clear – support the annual capital investment allocation, prioritization, and planning processes to better support investment programs and projects. Since that time, it has created a single enterprise wide investment gating model, created a sponsorship engagement model going from 0% of sponsors engaged at the start to 77% today, and enabled a culture of never stopping projects to one that stops non-viable efforts. With many other accomplishments, the core was a cultural transformation. Engagement of sponsors, enabling project management development opportunities and c